Glaxo Wellcome says it supports efforts by the US Senate Judiciary Committee to examine the risks to biomedical research and international patent protection of backing away from the intellectual property protection established by the General Agreement on Tariffs and Trade, as is proposed.
The proposal put forward by Senator David Pryor (Marketletters passim) would benefit one special interest, the generic drug industry, according to GW. Although GATT changed patent terms for all industries, Sen Pryor's proposal would roll back patents for only a small group of medicines that the generic industry wants to copy. This would result in fewer research incentives for a company seeking the next generation of medicines than a company seeking the next generation of roller skates or running shoes - "surely public policy turned on its head," said GW.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze